By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Hutchison China MediTech (Chi-Med) 

21st Floor, Hutchison House
10 Harcourt Road
Hong Kong      China
Phone: 852-2121-8200 Fax: 852-2121-8281


SEARCH JOBS

Hutchison China MediTech Limited, known as Chi-Med, is an innovative biopharmaceutical company aiming to become a global leader in the discovery, development and commercialisation of targeted therapies for oncology and immunological diseases.

YEAR FOUNDED:

2000

LEADERSHIP:

CEO: Christian Hogg

CFO: Johnny Cheng

CSO: Weiguo Su


Key Statistics


Email: info@chi-med.com
Ownership: Subsidiary

Web Site: Hutchison China MediTech (Chi-Med)
Employees:
Symbol: 
 



Industry
Pharmaceutical






Company News
Hutchison China MediTech (Chi-Med) Initiates A Phase II Study Of Savolitinib In Pulmonary Sarcomatoid Carcinoma 2/20/2017 6:27:28 AM
Hutchison China MediTech (Chi-Med) Launches Phase I Trial Of Novel FGFR Inhibitor In Australia 2/14/2017 11:50:01 AM
Hutchison China MediTech (Chi-Med): Initiates Phase I Of Novel FGFR Inhibitor HMPL-453 2/14/2017 9:31:35 AM
Hutchison China MediTech (Chi-Med): Savolitinib PRCC Results Presentation At ASCO GU 2/14/2017 9:30:18 AM
Hutchison China MediTech (Chi-Med) Initiates First-In-Human Clinical Trial Of Novel FGFR Inhibitor HMPL-453 In Australia 2/14/2017 6:31:56 AM
Hutchison China MediTech (Chi-Med) And AstraZeneca PLC (AZN) Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017 Genitourinary Cancers Symposium 2/14/2017 6:26:44 AM
Hutchison China MediTech (Chi-Med) To Announce 2016 Final Results 2/6/2017 10:50:13 AM
Hutchison China MediTech (Chi-Med) Appoints Industry Veteran Karen Ferrante To Board Of Directors 2/1/2017 8:25:17 AM
Hutchison China MediTech (Chi-Med) Release: Fruquintinib Combination Study In 1st-Line NSCLC 1/16/2017 7:48:44 AM
Hutchison China MediTech (Chi-Med) Release: Change Of Directors 1/16/2017 7:46:43 AM
12345678
//-->